Advanced Filters
noise

Diabetes Mellitus, Type 2 Clinical Trials

A listing of Diabetes Mellitus, Type 2 medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 1,183 clinical trials
X Xiang-Yu Zhao, MD PhD

Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL

To observe the safety and efficacy of Nanobody-Based CD5-targeted chimeric antigen receptor T cells in the treatment of refractory or relapsed T-ALL/NHL

3 - 70 years of age All Phase 1/2
N Nirav Shah, MD

CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies

This is a Phase I/II, interventional, single-arm, open-label, treatment study designed to evaluate the safety and efficacy of Interleukin-7 and Interleukin-15 (IL-7/IL-15) manufactured chimeric antigen receptor (CAR)-20/19-T cells as well as the feasibility of a flexible manufacturing schema in adult patients with B cell malignancies that have failed prior therapies.

18 - 80 years of age All Phase 1/2
S Site Public Contact

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO.

18 - 39 years of age All Phase N/A
K Kees-Jan Pronk, MD, PhD

Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML

It is a randomized phase 3 study comparing two conditioning regimens in children with Acute Myeloid Leukemia, AML, undergoing allogenic stem cell transplantation. The primary aim is to investigate if a conditioning regimen containing one alkylator (Bu) combined with two antimetabolites (Clo and Flu) results in superior 2-year acute grade …

- 18 years of age All Phase 3
M Medical College of Wisconsin Cancer Center Clinical Trials Office

Long-term Follow-up Study of Patients Receiving CAR-T Cells

This protocol is designed as a long-term follow-up study of participants who will receive CAR-T cells as part of a clinical trial at the Medical College of Wisconsin/ Froedtert Hospital. The clinical trials include the following: Phase 1 Study of CAR-20/19-T Cells in Patients with Relapsed Refractory B Cell Malignancies …

18 - 80 years of age All Phase N/A

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients with advanced B-cell malignancies.

18 years of age All Phase 1
J J. Nuver, MD, PhD

Early Ageing During Therapy in AYA Cancer Patients

Longitudinal cohort study; measurements before start of systemic therapy and one year later.

18 - 39 years of age All Phase N/A
L Lugui Qiu, Doctor

JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas

Indolent T/NK-cell lymphomas are a heterogeneous group of lymphoproliferative diseases originating from T/NK cells, characterized by slow growth and proliferation, but currently remain incurable. For indolent T/NK-cell lymphomas that are unresponsive to first-line treatment, there are few treatment options available and the prognosis is poor. This study is an open-label, …

18 years of age All Phase 2

Effect of APA on Sleep Quality in Children With Cancer From 5 to 16 Years

Main objective : Evaluate the effect of adapted physical activity on the sleep of children with cancer from 5 to 16 Hypothesis : Practice daily adapted physical activity improve the sleep of the 5 to 16 children with cancer

5 - 16 years of age All Phase N/A

Biocollection in MyeloDysplastic Syndrome (P-MDS)

Myelodysplastic syndromes (MDS) are chronic myeloid hemopathies characterized by ineffective hematopoiesis (with peripheral cytopenias) and which contrast with a marrow of normal richness. MDS is considered one of the four most common blood diseases. The incidence is estimated at 4,059 cases / year in 2012 with an average age of …

18 years of age All Phase N/A

Simplify language using AI